Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of Myasthenia gravis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  George, Sandra ^a,c   Paulick, Silvia ^a   Knuẗter, Ilka ^b   Rob̈er, Nadja ^c   Hiemann, Rico ^b   Roggenbuck, Dirk ^a,b   Conrad, Karsten ^c   Kup̈per, Jan Heiner ^a  

^a BRANDENBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^b GA GENERIC ASSAYS GMBH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENTARY DNA; MESSENGER RNA; MUSCLE SPECIFIC KINASE; MUSCLE SPECIFIC KINASE AUTOANTIBODY; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD DONOR; CELL CLONE; CELL CULTURE; CELL MEMBRANE; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; HEP 2 M4 CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MYASTHENIA GRAVIS; NUCLEOTIDE SEQUENCE; RADIOIMMUNOASSAY; STABLE EXPRESSION;

AUTOANTIBODIES; AUTOMATION; CELL LINE; CELL PROLIFERATION; CELL SHAPE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MYASTHENIA GRAVIS; ORGAN SPECIFICITY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 84897546850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083924     Document Type: Article

References (54)

1. Phillips LH (2003) The epidemiology of myasthenia gravis. Ann N Y Acad Sci 998: 407-412.
2. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843-2854. (Pubitemid 44684466)
3. Lang B, Vincent A (2009) Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol 9: 336-340.
4. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
5. Simpson JA (1960) Myasthenia Gravis: A New Hypothesis. Scott Med J 5: 419-436.
6. Lefvert AK, Bergstrom K (1978) Acetylcholine receptor antibody in myasthenia gravis: purification and characterization. Scand J Immunol 8: 525-533. (Pubitemid 9065179)
7. Sanders DB, Cobb EE, Winfield JB (1978) Neonatal experimental autoimmune myasthenia gravis. Muscle & nerve 1: 146-150.
8. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, et al. (2001) Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368. (Pubitemid 32224355)
9. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, et al. (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55: 580-584. (Pubitemid 38391977)
10. Romi F, Aarli JA, Gilhus NE (2005) Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 12: 413-418. (Pubitemid 40768658)
11. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978-1980. (Pubitemid 36736017)
12. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, et al. (2002) Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Laboratory investigation; a journal of technical methods and pathology 82: 1139-1146.
13. Vincent A, McConville J, Farrugia ME, Newsom-Davis J (2004) Seronegative myasthenia gravis. Semin Neurol 24: 125-133. (Pubitemid 38823786)
14. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, et al. (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57: 444-448. (Pubitemid 40343969)
15. Jacob S, Viegas S, Leite MI, Webster R, Cossins J, et al. (2012) Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Archives of neurology 69: 994-1001.
16. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, et al. (2008) IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain: a journal of neurology 131: 1940-1952.
17. Hiemann R, Buttner T, Krieger T, Roggenbuck D, Sack U, et al. (2009) Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev 9: 17-22.
18. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: 34-46.
19. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
20. Rodiger S, Schierack P, Bohm A, Nitschke J, Berger I, et al. (2013) A highly versatile microscope imaging technology platform for the multiplex real-time detection of biomolecules and autoimmune antibodies. Adv Biochem Eng Biotechnol 133: 35-74.
21. Willitzki A, Hiemann R, Peters V, Sack U, Schierack P, et al. (2012) New platform technology for comprehensive serological diagnostics of autoimmune diseases. Clin Dev Immunol 2012: 284740-284748.
22. Pozarowski P, Darzynkiewicz Z (2004) Analysis of cell cycle by flow cytometry. Methods Mol Biol 281: 301-311.
23. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, et al. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191. (Pubitemid 28248804)
24. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386-389. (Pubitemid 28269714)
25. Grassi G, Maccaroni P, Meyer R, Kaiser H, D'Ambrosio E, et al. (2003) Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24: 1625-1635. (Pubitemid 37304667)
26. Gerhäuser C (2013) Cancer cell metabolism, epigenetics and the potential influence of dietary components - A perspective. Biomedical Research 23: 91-98.
27. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, et al. (2006) Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175: 107-117. (Pubitemid 43765734)
28. Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, et al. (2012) Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol 69: 453-460.
29. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, et al. (2006) Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116: 1016-1024.
30. Shigemoto K, Kubo S, Jie C, Hato N, Abe Y, et al. (2008) Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 1132: 93-98. (Pubitemid 351841345)
31. Cavalcante P, Bernasconi P, Mantegazza R (2012) Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 25: 621-629.
32. Cole RN, Reddel SW, Gervasio OL, Phillips WD (2008) Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63: 782-789. (Pubitemid 351945537)
33. Gilhus NE (2012) Myasthenia and the neuromuscular junction. Curr Opin Neurol 25: 523-529.
34. Meriggioli MN, Sanders DB (2012) Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 8: 427-438.
35. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, et al. (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain: a journal of neurology 126: 2304-2311.
36. Lavrnic D, Losen M, Vujic A, De BM, Hajdukovic LJ, et al. (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 76: 1099-1102. (Pubitemid 41081284)
37. Vincent A, Bowen J, Newsom-Davis J, McConville J (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2: 99-106. (Pubitemid 37443330)
38. Farrugia ME, Kennett RP, Newsom-Davis J, Hilton-Jones D, Vincent A (2006) Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle & nerve 33: 568-570.
39. Meyer A, Levy Y (2010) Geoepidemiology of myasthenia gravis [corrected]. Autoimmun Rev 9: A383-A386.
40. Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, et al. (2010) Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle & nerve 41: 370-374.
41. Wolfe GI, Oh SJ (2008) Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci 1132: 71-75. (Pubitemid 351841348)
42. Caress JB, Hunt CH, Batish SD (2005) Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 62: 1002-1003. (Pubitemid 40973464)
43. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, et al. (2007) Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68: 609-611.
44. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, et al. (2008) Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 1132: 76-83. (Pubitemid 351841355)
45. Vincent AC, McConville J, Newsom-Davis J (2005) Is " seronegative" MG explained by autoantibodies to MuSK? Neurology 64: 399.
46. Hiemann R, Hilger N, Michel J, Nitschke J, Bohm A, et al. (2007) Automatic analysis of immunofluorescence patterns of HEp-2 cells. Ann N Y Acad Sci 1109: 358-371. (Pubitemid 47511379)
47. Egerer K, Roggenbuck D, Hiemann R, Weyer MG, Buttner T, et al. (2010) Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther 12: R40.
48. Kivity S, Gilburd B, Agmon-Levin N, Carrasco MG, Tzafrir Y, et al. (2012) A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol 31: 503-509.
49. Knutter I, Hiemann R, Brumma T, Buttner T, Grossmann K, et al. (2012) Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. Arthritis research & therapy 14: R271.
50. Grossmann K, Roggenbuck D, Schroder C, Conrad K, Schierack P, et al. (2011) Multiplex assessment of non-organ-specific autoantibodies with a novel microbead-based immunoassay. Cytometry A 79: 118-125.
51. Runge R, Hiemann R, Wendisch M, Kasten-Pisula U, Storch K, et al. (2012) Fully automated interpretation of ionizing radiation-induced gammaH2AX foci by the novel pattern recognition system AKLIDES(R). Int J Radiat Biol 88: 439-447.
52. Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, et al. (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67: 505-507. (Pubitemid 44214984)
53. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, et al. (2007) Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 14: 1029-1034. (Pubitemid 47300778)
54. Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, et al. (2012) Recommendations for myasthenia gravis clinical trials. Muscle & nerve 45: 909-917.